Addition of Etoricoxib During Concurrent Chemo-radiation of Cervical Cancer Patients Could Result in Faster Resolution of Gross Disease: A Prospective Single-Institution Study

Dhar, Sovan Sarang; Shahi, Uday Pratap; Kumar, Deepak; Mishra, Ritusha; Kaser, Prashant; Dewangan, Satish; Mandal, Abhijit; Choudhary, Sunil; Aggarwal, Lalit Mohan; Asthana, Anjana; Pradhan, Satyajit

doi:10.1007/s40944-019-0331-0

Cited by 8 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Activation of pro-apoptotic Bax • Downregulates Sp transcription factors and Sp-regulated genes (include survivin, bcl-2, EGFR, cyclin D1, p65 subunit of NFκB and VEGF) • induced ROS and decreased microRNA-27a levels in CRC • Decreased M2 macrophages recruitment, cancer-related inflammation, and angiogenesis (Bank et al 2008 ; Li et al 2015 ; Yin et al 2016 ; Sui et al 2018 ) 7 Lumiracoxib COX-2 NSCLC • Synergistic effect of combination lumiracoxib and docetaxel (better efficacy) (Hao et al 2008 ; Emam Kassab 2019 ) 8 Etoricoxib COX-2 Cervical cancer, CRC • Selective COX-2 inhibitor induces apoptosis • Nanoparticle (CKGPEC stabilized etoricoxib) showed improved efficacy in CRC. • Concurrent addition etoricoxib improves chemo-radiation combination in cervical cancer (Sharma et al 2010 ; Dhar et al 2020 ; Malviya et al 2020 ) 9 Rofecoxib COX-2 CRC, pancreatic cancer, NSCLC • In combination with Gefitinib showed better efficacy in NSCLC. (EGFR increases COX-2 expression) • Induces cell cycle arrest by decreasing cyclin D1/PRAD1expression and increasing expression cell cycle arrest genes, including p21/WAF1, p33/ING, GADD34, and GADD45.…”

Section: Therapeutics Avenues Targeting Cancer Provoked By Mutagensmentioning

confidence: 99%

“…• Induces apoptosis via a caspase-3 pathway (Ho Woo et al 2004;Shiiba et al 2017) • In combination with carboplatin, reduce tumor cell proliferation (synergetic effect) (Noguchi et al 1995;Mohammed et al 2002;Campione et al 2015;SILVA et al 2017) • Concurrent addition etoricoxib improves chemo-radiation combination in cervical cancer (Sharma et al 2010;Dhar et al 2020;Malviya et al 2020) 9…”

Section: Anti-inflammatory Nonsteroidal Anti-inflammatory Drugs As Chemical Cancer Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Unboxing the molecular modalities of mutagens in cancer

Kumari

Sharma

Advani

et al. 2021

Environ Sci Pollut Res

View full text Add to dashboard Cite

Graphical abstract The etiology of the majority of human cancers is associated with a myriad of environmental causes, including physical, chemical, and biological factors. DNA damage induced by such mutagens is the initial step in the process of carcinogenesis resulting in the accumulation of mutations. Mutational events are considered the major triggers for introducing genetic and epigenetic insults such as DNA crosslinks, single- and double-strand DNA breaks, formation of DNA adducts, mismatched bases, modification in histones, DNA methylation, and microRNA alterations. However, DNA repair mechanisms are devoted to protect the DNA to ensure genetic stability, any aberrations in these calibrated mechanisms provoke cancer occurrence. Comprehensive knowledge of the type of mutagens and carcinogens and the influence of these agents in DNA damage and cancer induction is crucial to develop rational anticancer strategies. This review delineated the molecular mechanism of DNA damage and the repair pathways to provide a deep understanding of the molecular basis of mutagenicity and carcinogenicity. A relationship between DNA adduct formation and cancer incidence has also been summarized. The mechanistic basis of inflammatory response and oxidative damage triggered by mutagens in tumorigenesis has also been highlighted. We elucidated the interesting interplay between DNA damage response and immune system mechanisms. We addressed the current understanding of DNA repair targeted therapies and DNA damaging chemotherapeutic agents for cancer treatment and discussed how antiviral agents, anti-inflammatory drugs, and immunotherapeutic agents combined with traditional approaches lay the foundations for future cancer therapies.

show abstract

Section: Therapeutics Avenues Targeting Cancer Provoked By Mutagensmentioning

confidence: 99%

Section: Anti-inflammatory Nonsteroidal Anti-inflammatory Drugs As Chemical Cancer Preventionmentioning

confidence: 99%

Unboxing the molecular modalities of mutagens in cancer

Kumari

Sharma

Advani

et al. 2021

Environ Sci Pollut Res

View full text Add to dashboard Cite

show abstract

Being sick to a cancer patient: pathways of delay in help seeking and diagnosis of cancer in India

George

2022

J. Soc. Econ. Dev.

View full text Add to dashboard Cite

There is evidence that cancer mortality and morbidity could be reduced when the disease is diagnosed and treated at an early stage. The paper examines the pathways of delay of cancer diagnosis in an Indian setting. It draws on a qualitative study conducted among cancer survivors and family members of cancer patients in the city of Bengaluru, South India. The results show that a substantial part of the delay occurred at the stage of initial formal help seeking wherein patient and family-led, disease-related and systemic factors together played a major role. Patient-led factors included trivialisation and normalisation of symptoms as part of general fatigue and aging; unrealistic risk perceptions that linked causality of cancer merely to heredity and behavioural risk factors; fear of being diagnosed as cancer patient; gender related reasons including family’s gender performance expectation, lower agency of women to seek help and lower prioratisation of women’s health in the household and access related issues including financial constraints and unavailability of specialised hospitals nearby. Disease-related factors included the presence of comorbidity, cancer’s mimicking of symptoms of other diseases and absence of distinguishable symptoms at the initial stage for certain types of cancers. The practitioner-led and system-led factors such as trivialisation of symptoms by general practitioners, non cancer-specific referrals, and lack of cancer screening facilities accounted for a major part of delay after the formal help seeking. The paper argues that the mere knowledge of cancer symptoms did not always lead to early diagnosis due to the interplay of these factors. The ongoing cancer prevention and control interventions in India need to be informed of these micro level factors while developing strategies to prevent avoidable delays in cancer diagnosis.

show abstract